This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharmaceuticals Corporation.
Reference
Loong HH, et al. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Effectiveness and Resource Allocation : 7 Nov 2020. Available from: URL: https://doi.org/10.1186/s12962-020-00244-6
Rights and permissions
About this article
Cite this article
Ceritinib valuable treatment option in advanced ALK-positive lung cancer. PharmacoEcon Outcomes News 866, 4 (2020). https://doi.org/10.1007/s40274-020-7264-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7264-9